文献速递基础与转化研究临床试验与 GCP

造血干/祖细胞基因治疗Hurler综合征后的早期骨骼结局

Early skeletal outcomes after hematopoietic stem and progenitor cell gene therapy for Hurler syndrome.
PubMed 文献 · Sci Transl Med · 2024-05-01

8例MPSIH患者(治疗时平均年龄1.9岁)在1/2期临床试验(NCT03488394)中接受慢病毒HSPC-GT,评估骨骼发育不良指标至治疗后4年,并与HSCT外部队列回顾性比较。中位随访3.78年时,HSPC-GT组纵向生长位于WHO参考范围内,中位身高增幅大于HSCT组3年随访;关节活动度完全且更早正常化;髋臼指数和迁移百分比进行性下降,脊柱MRI评分稳定。临床、功能和影像学指标提示HSPC-GT对MPSIH典型骨骼特征有早期有益效应,需更长随访才能得出明确结论。

要点

  • HSPC-GT后中位随访3.78年,患者纵向生长位于WHO参考范围,中位身高增幅大于HSCT组3年随访。
  • HSPC-GT组关节活动度完全且更早正常化,髋臼指数和迁移百分比进行性下降。
  • 脊柱MRI评分在HSPC-GT后稳定,临床、功能和影像学指标提示早期有益效应。

核心结论

  • 临床、功能和影像学指标提示HSPC-GT对MPSIH典型骨骼特征有早期有益效应,但需更长随访才能对HSPC-GT影响MPSIH骨骼发育不良得出明确结论。

研究设计与样本

  • 1/2期临床试验(NCT03488394)纳入8例MPSIH患者,治疗时平均年龄1.9岁,接受慢病毒HSPC-GT。
  • 在基线和治疗后至4年的多个时间点评估骨骼发育不良的临床、功能和影像学指标。
  • 特定骨骼指标与HSCT治疗的外部队列进行回顾性比较。

主要发现

  • HSPC-GT后中位随访3.78年,所有患者纵向生长位于WHO参考范围内,中位身高增幅大于HSCT组3年随访。
  • HSPC-GT组关节活动度完全且更早正常化,髋臼指数和迁移百分比进行性下降,提示髋臼发育不良减轻。
  • 脊柱MRI评分显示的典型脊柱改变在HSPC-GT后稳定。

关键数值与推荐

  • 髋臼指数和迁移百分比在HSPC-GT后进行性下降。
  • 脊柱MRI评分在HSPC-GT后稳定。
  • 中位随访3.78年时,HSPC-GT组纵向生长位于WHO参考范围内。

局限性

  • 原文结论指出需更长随访才能对HSPC-GT影响MPSIH骨骼发育不良得出明确结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mucopolysaccharidosis type I Hurler (MPSIH) is characterized by severe and progressive skeletal dysplasia that is not fully addressed by allogeneic hematopoietic stem cell transplantation (HSCT). Autologous hematopoietic stem progenitor cell-gene therapy (HSPC-GT) provides superior metabolic correction in patients with MPSIH compared with HSCT; however, its ability to affect skeletal manifestations is unknown. Eight patients with MPSIH (mean age at treatment: 1.9 years) received lentiviral-based HSPC-GT in a phase 1/2 clinical trial (NCT03488394). Clinical (growth, measures of kyphosis and genu velgum), functional (motor function, joint range of motion), and radiological [acetabular index (AI), migration percentage (MP) in hip x-rays and MRIs and spine MRI score] parameters of skeletal dysplasia were evaluated at baseline and multiple time points up to 4 years after treatment. Specific skeletal measures were retrospectively compared with an external cohort of HSCT-treated patients. At a median follow-up of 3.78 years after HSPC-GT, all patients treated with HSPC-GT exhibited longitudinal growth within WHO reference ranges and a median height gain greater than that observed in patients treated with HSCT after 3-year follow-up. Patients receiving HSPC-GT experienced complete and earlier normalization of joint mobility compared with patients treated with HSCT. Mean AI and MP showed progressive decreases after HSPC-GT, suggesting a reduction in acetabular dysplasia. Typical spine alterations measured through a spine MRI score stabilized after HSPC-GT. Clinical, functional, and radiological measures suggested an early beneficial effect of HSPC-GT on MPSIH-typical skeletal features. Longer follow-up is needed to draw definitive conclusions on HSPC-GT's impact on MPSIH skeletal dysplasia.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Consiglieri G, Tucci F, De Pellegrin M, et al. Early skeletal outcomes after hematopoietic stem and progenitor cell gene therapy for Hurler syndrome. Sci Transl Med. 2024. PMID: 38691622. doi:10.1126/scitranslmed.adi8214

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。